The first effective and safe reversal agent to stop or prevent life-threatening bleeding in patients taking the emerging generation of anticoagulants.broad
StopBleeding · Horizon Europe grant · 2022-09-01–2025-03-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATOROPEN-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATOROPEN-01. CORDIS record →
Objective
50 Million patients worldwide use oral anticoagulants to prevent venous thrombosis and stroke. Since the last decade, unpredictable and risky indirect anticoagulant treatments are being replaced by the latest generation of blood-thinning medication: Factor Xa Direct Oral Anticoagulants (FXa-DOACs, used by >10 million patients in EU+US). With superior predictability, efficacy and safety profiles, these life-saving medications remain associated with a risk of uncontrolled and severe bleeding. Alarmingly, there is no safe reversal agent that restores blood clotting in patients who take FXa-DOACs, resulting in life-threatening bleeding episodes and >400k hospital admissions. To address the urgent unmet need, VarmX has developed VMX-C001, the first effective and safe reversal agent to FXa-DOACs. VarmX requests a €2,5M in grant and €15M in equity EIC to accelerate upscaling and improve the cost-effectiveness of the complex manufacturing process required to produce VMX-C001.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| VARMX BV | NL | coordinator | €2,500,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.